Scott was specifically asked a question about what he felt was the biggest downside risk. He had to say something. I think it speaks volumes that the biggest perceived risk from a well informed large shareholder for PAR is actually IP risk. IP risk is a risk for any drug, software, technology or device company that has patent protection before entering a large market and looking to dislodge encumbent players.
This risk though is still a decent viable risk given the generic nature of the drug and reliance on a third party contract but again it’s amazing that Pre approval the risk is not the actual efficacy or safety of the drug.
As an example Medtronic are in the news today for legal action regarding patent infringement in their TAVR device from a much smaller competitor. They have very deep pockets and can deal with this. But no company is immune to this risk.
Therefore, I believe that prior to the completion of phase three trials but after some encouraging read outs we will partner with a major for their sales, marketing and distribution network but also their deep pockets, reputation and ability to defend any legal action brought on by disgruntled competition in relation to our IP.
DYOR and IMO.
PAR Price at posting:
$3.56 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)